You can be consistent with your workouts, thoughtful about nutrition, and successful in your career—and still find yourself waking up drenched in sweat, struggling through disrupted sleep, or feeling uncomfortable in a body that suddenly seems unfamiliar.
For many women, the hardest part is getting a clear explanation of what is happening and what might help.
Menopause care deserves that conversation. And in 2026, an important FDA labeling change has given women another reason to revisit their options.
On February 12, 2026, the FDA approved revised labeling for an initial six menopausal hormone therapy products, removing cardiovascular disease, breast cancer, and probable dementia statements from their boxed warnings. The change followed an initiative announced in November 2025. It does not mean hormone therapy is risk-free or appropriate for every woman. FDA
What it does mean is that the discussion should be more specific: your symptoms, your health history, your stage of menopause, and the treatment being considered.
Here is what women should understand before making a decision.
What changed about menopause hormone therapy in 2026?
Menopausal hormone therapy, also called MHT, HT, or hormone replacement therapy, uses estrogen, sometimes combined with a progestogen, to treat particular menopause-related symptoms.
The FDA’s February announcement covered an initial group of products across systemic combination therapy, systemic estrogen alone, systemic progestogen therapy, and local vaginal estrogen. It was not a blanket announcement that every product label changed simultaneously. FDA
The broader labeling initiative included these distinctions:
| Labeling issue | What the FDA requested |
| Cardiovascular disease and breast cancer | Remove these statements from boxed warnings while retaining relevant warnings in systemic product labeling. |
| Probable dementia | Remove the warning from the labeling. |
| Endometrial cancer | Retain the boxed warning on systemic estrogen-only products. |
| Treatment timing | Add information about starting systemic treatment for moderate-to-severe hot flashes before age 60 or within 10 years of menopause. |
| Local vaginal estrogen | Focus safety information more directly on the local formulation. |
The FDA also requested removal of the general “lowest effective dose for the shortest amount of time” recommendation from the boxed warning. That does not eliminate the need for appropriate dosing and periodic review. FDA
A change in warning placement is not a declaration that the underlying medical risks have disappeared.
Why were the hormone therapy warnings reconsidered?
Much of the public concern about hormone therapy followed findings from the Women’s Health Initiative, or WHI.
Those large studies provided important safety information. However, the average participant was approximately 63—older than many women first seeking treatment for disruptive menopause symptoms.
FDA’s reassessment considered how age, treatment timing, and the differences between systemic and local therapy affect the interpretation of those findings. FDA
The appropriate lesson is not to dismiss the earlier research. It is to apply evidence to the woman and treatment in front of the clinician.
A healthy woman seeking relief from hot flashes near menopause is facing a different decision from an older woman considering starting systemic hormones many years later.
What can menopause hormone therapy help with?
Hot flashes and night sweats
Hormone therapy remains the most effective treatment for bothersome vasomotor symptoms, the medical term for hot flashes and night sweats.
These symptoms can interrupt meetings, disturb sleep, and make daily life unpredictable. Treatment may meaningfully reduce their frequency and severity. PubMed
Sleep disrupted by menopause symptoms
When night sweats repeatedly wake you, treating those symptoms may help you sleep more comfortably.
Hormone therapy may also help some women with menopause-related mood and sleep difficulties. However, persistent insomnia, anxiety, or low mood deserves its own assessment rather than an assumption that estrogen will resolve everything. ACOG
Vaginal dryness and painful sex
Declining estrogen can affect vaginal and urinary tissues. Symptoms may include dryness, irritation, and discomfort with sexual activity.
Low-dose vaginal estrogen can address local symptoms with much less systemic exposure than treatment intended to circulate throughout the body. Some women using systemic therapy still need additional local treatment. The Menopause Society
Bone loss
Hormone therapy can prevent bone loss and reduce fracture risk. Whether it is the appropriate option depends on your age, symptoms, fracture risk, and other available treatments. PubMed
The objective is a treatment plan with specific goals—not a promise that hormones will fix every change associated with midlife.
Who may be a good candidate for hormone therapy?
For women with bothersome symptoms and no contraindications, the benefit-risk balance is generally more favorable when treatment begins before age 60 or within 10 years of menopause onset.
Starting systemic therapy later can involve higher absolute risks of coronary heart disease, stroke, blood clots, and dementia. PubMed
These timing considerations guide a discussion. They are not a prescription based on age alone.
An evaluation should consider:
- Which symptoms are affecting your daily life.
- Your menstrual history and time since menopause.
- Whether you have a uterus.
- Your personal and family medical history.
- Current medications and previous treatment experiences.
- Your preferences about treatment and follow-up.
You do not have to reach a breaking point before asking for help. Symptoms that interfere with sleep, comfort, relationships, or work deserve attention.
What risks remain after the FDA labeling changes?
Breast cancer
Breast cancer risk requires a discussion of the particular regimen, duration, and the woman’s history.
Combined estrogen-progestogen therapy is associated with an increased breast cancer risk; estrogen-only therapy has a different evidence profile. The two should not be treated as interchangeable.
A personal history of hormone-sensitive breast cancer is an important reason to discuss nonhormonal options and specialist guidance. ACOG
Blood clots and stroke
Route of administration matters. Oral estrogen increases clot risk, while transdermal estrogen, such as a patch or gel, may carry a lower risk.
That possible advantage does not make transdermal therapy risk-free or automatically appropriate for someone with a clotting history. The Menopause Society
Endometrial cancer
Systemic estrogen without adequate protection can stimulate the uterine lining and increase endometrial cancer risk.
Women who have a uterus generally need a progestogen or another appropriate protective regimen when using systemic estrogen. This is a key reason prescribing must account for whether a woman has had a hysterectomy. ACOG
Side effects and bleeding
Breast tenderness, nausea, and spotting can occur. Report bleeding changes to your clinician rather than assuming they are harmless.
A history of unexplained uterine bleeding, liver disease, blood clots, cardiovascular disease, or certain cancers may make systemic therapy inappropriate or require specialist assessment. The Menopause Society
What is the difference between systemic and vaginal estrogen?
Systemic hormone therapy reaches the bloodstream at levels intended to treat symptoms throughout the body, such as hot flashes.
Low-dose vaginal estrogen primarily treats local vaginal and urinary symptoms. It generally does not provide the systemic treatment needed for hot flashes.
This distinction is more useful than simply asking whether a treatment contains estrogen. The product, dose, and intended effect matter. Some vaginal rings deliver systemic therapy, so vaginal placement alone does not tell you how the medicine works. The Menopause Society
Ask your clinician to explain which symptoms your prescription is intended to address.
Are bioidentical hormones safer?
“Bioidentical” does not automatically mean safer, more effective, or custom compounded.
The term generally describes hormones with the same molecular structure as hormones made by the body. FDA-approved products can meet that definition.
Compounded preparations are not FDA approved. ACOG recommends FDA-approved menopausal hormone therapies over compounded bioidentical preparations when approved options can meet the patient’s needs. Claims that custom-compounded hormones are inherently safer or more effective are not supported by adequate evidence. ACOG
Personalized care means selecting treatment based on your circumstances. It does not necessarily require a custom-mixed medication.
Do you need hormone testing before starting HRT?
Routine hormone testing is generally not recommended before starting treatment for typical menopausal symptoms. Hormone levels fluctuate during the transition, so one result may offer little useful information. ACOG
For otherwise healthy people aged 45 or older with typical symptoms, menopause assessment is usually clinical rather than dependent on laboratory confirmation. Testing can be appropriate in younger patients or when the diagnosis is uncertain. NICE
That does not mean laboratory work is never useful. A clinician may investigate other possible explanations for symptoms or evaluate relevant health risks.
The question should be: What decision will this test help us make?
Will hormone therapy help with menopause weight gain?
Hormone therapy should not be presented as a weight-loss treatment or a guaranteed solution for abdominal fat.
The Menopause Society identifies symptom treatment and bone protection among established indications. It cautions against extending hormone therapy’s benefits into unsupported claims. menopause.org
For women concerned about body composition, the conversation can include nutrition, resistance training, sleep, medications, and metabolic health. Treating disruptive menopause symptoms may make it easier to follow a health plan, but that is different from promising weight loss from hormones.
Your concerns deserve an evaluation that looks beyond a single prescription.
Does hormone therapy prevent heart disease or dementia?
Hormone therapy should not be started solely to prevent cardiovascular disease or dementia in women undergoing menopause at the usual age.
The Menopause Society distinguishes treatment of menopausal symptoms from prescribing hormones for primary prevention of these diseases. menopause.org
Removing a warning does not establish a new preventive indication.
Women concerned about cardiovascular or cognitive health should discuss the risk factors and preventive strategies relevant to their own history.
What if hormones are not right for you?
You still have treatment options.
Depending on the symptoms, an individualized plan may include nonhormonal prescription treatment, menopause-specific cognitive behavioral therapy, vaginal moisturizers and lubricants, or other targeted care. NICE includes hormonal and nonhormonal approaches in its menopause guidance. NICE
Not choosing hormones should not mean leaving with no plan.
A useful consultation ends with an explanation of the options, the reason for the recommendation, and a clear next step.
Questions to bring to your menopause appointment
Write down your three most disruptive symptoms and how they affect your life. Then consider asking:
- Do these symptoms fit perimenopause or menopause, or should we investigate another cause?
- What improvement should I reasonably expect from treatment?
- Would systemic treatment, local treatment, or a nonhormonal option best fit my symptoms?
- How does my history affect breast cancer, clotting, stroke, or uterine risks?
- If I have a uterus, how will the lining be protected?
- Would testing change the treatment decision?
- When will we review progress, side effects, and whether treatment remains appropriate?
These questions make the decision more concrete and give you a way to assess whether the plan is working.
Frequently Asked Questions
Did the FDA remove the HRT boxed warning in 2026?
On February 12, 2026, FDA approved revised labeling for an initial six products, removing cardiovascular disease, breast cancer, and probable dementia statements from their boxed warnings. Product-specific labeling should still be checked. FDA
Does the label change mean HRT is safe for everyone?
No. Relevant risks, contraindications, treatment timing, and individual health history still matter. FDA retained cardiovascular and breast cancer information in systemic labeling and the endometrial cancer boxed warning for systemic estrogen-only products. FDA
Can you start hormone therapy during perimenopause?
It may be considered for appropriate symptoms during the transition. An evaluation should address bleeding patterns, pregnancy prevention needs, and treatment suitability. Menopause care does not always require waiting until periods have stopped completely. NICE provides treatment guidance for both perimenopause and menopause. NICE
Do women with a uterus need progesterone?
Women using systemic estrogen generally need endometrial protection, commonly provided by progesterone or another progestogen. The requirement differs for low-dose local vaginal estrogen, so confirm the exact regimen with your clinician. ACOG
Do you have to stop hormone therapy at age 65?
No automatic stopping age applies to everyone. Continuing treatment can be considered for persistent symptoms or other appropriate indications after reviewing benefits and risks. Starting treatment later and continuing an established treatment are different decisions. menopause.org
How long can you take hormone therapy?
Duration depends on the indication, symptom burden, evolving risks, and preferences. Longer treatment requires shared decision-making and periodic reevaluation rather than an automatic renewal. PubMed
Are estrogen patches safer than pills?
Transdermal therapy may reduce clotting and stroke risk compared with oral treatment, but the best route depends on the individual. A patch does not eliminate all hormone-related risks. menopause.org.au
Can women with a breast cancer history use vaginal estrogen?
Some may be candidates for low-dose vaginal treatment after nonhormonal options have failed, through an individualized discussion with their treating clinicians. This is different from prescribing systemic hormone therapy. menopause.org.au
What if menopause happens unusually early?
Premature or early menopause needs specific evaluation. In the absence of contraindications, hormone therapy is often recommended until approximately the usual menopause age because the benefits and risks differ from those of starting treatment later in life. menopause.org.au
Get a clearer plan for your next stage of health
You deserve to feel heard and to understand your options.
At 1st Optimal, we approach women’s health with attention to life stage, symptoms, goals, and the bigger picture. A conversation can help identify appropriate next steps, including evaluation by a licensed medical provider when indicated.
Whether you are dealing with disruptive nights, uncomfortable symptoms, or questions about hormone therapy, you do not have to sort through conflicting headlines alone.
Book a free consultation with 1st Optimal to discuss your concerns and explore your next steps.
This article provides general education and does not replace individualized medical advice. Treatment decisions should be made with a licensed healthcare professional.
